|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EHBP1 |
Gene summary for EHBP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EHBP1 | Gene ID | 23301 |
| Gene name | EH domain binding protein 1 | |
| Gene Alias | HPC12 | |
| Cytomap | 2p15 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A140VK17 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23301 | EHBP1 | CCI_1 | Human | Cervix | CC | 1.79e-17 | 1.14e+00 | 0.528 |
| 23301 | EHBP1 | CCI_2 | Human | Cervix | CC | 1.69e-13 | 1.25e+00 | 0.5249 |
| 23301 | EHBP1 | CCI_3 | Human | Cervix | CC | 1.34e-21 | 1.24e+00 | 0.516 |
| 23301 | EHBP1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 5.52e-08 | -4.70e-01 | 0.0155 |
| 23301 | EHBP1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.79e-06 | -4.96e-01 | -0.1808 |
| 23301 | EHBP1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.00e-07 | -5.47e-01 | -0.1207 |
| 23301 | EHBP1 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.85e-17 | -5.76e-01 | -0.1464 |
| 23301 | EHBP1 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.29e-05 | -3.77e-01 | -0.1001 |
| 23301 | EHBP1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 8.60e-03 | -6.61e-01 | -0.1706 |
| 23301 | EHBP1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 6.38e-05 | -8.01e-01 | -0.2061 |
| 23301 | EHBP1 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.73e-02 | -4.76e-01 | -0.0842 |
| 23301 | EHBP1 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.00e-08 | -5.22e-01 | 0.096 |
| 23301 | EHBP1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.58e-05 | -4.27e-01 | 0.0338 |
| 23301 | EHBP1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.24e-04 | -3.48e-01 | 0.0674 |
| 23301 | EHBP1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.53e-02 | -4.37e-01 | 0.0588 |
| 23301 | EHBP1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.53e-07 | -3.39e-01 | 0.294 |
| 23301 | EHBP1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 6.01e-03 | -5.47e-01 | 0.2585 |
| 23301 | EHBP1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.07e-07 | -4.18e-01 | 0.3005 |
| 23301 | EHBP1 | A001-C-207 | Human | Colorectum | FAP | 4.56e-03 | 1.35e-02 | 0.1278 |
| 23301 | EHBP1 | A015-C-203 | Human | Colorectum | FAP | 3.18e-30 | -4.13e-01 | -0.1294 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EHBP1 | SNV | Missense_Mutation | novel | c.289G>C | p.Glu97Gln | p.E97Q | Q8NDI1 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| EHBP1 | SNV | Missense_Mutation | novel | c.1392N>C | p.Lys464Asn | p.K464N | Q8NDI1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EHBP1 | SNV | Missense_Mutation | novel | c.1141N>G | p.Pro381Ala | p.P381A | Q8NDI1 | protein_coding | tolerated(0.81) | benign(0.021) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| EHBP1 | SNV | Missense_Mutation | c.469N>T | p.Ile157Phe | p.I157F | Q8NDI1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| EHBP1 | SNV | Missense_Mutation | novel | c.65N>T | p.Ala22Val | p.A22V | Q8NDI1 | protein_coding | deleterious(0.01) | possibly_damaging(0.902) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| EHBP1 | SNV | Missense_Mutation | novel | c.3236N>A | p.Ala1079Glu | p.A1079E | Q8NDI1 | protein_coding | tolerated(0.23) | probably_damaging(0.999) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| EHBP1 | SNV | Missense_Mutation | c.2923G>A | p.Glu975Lys | p.E975K | Q8NDI1 | protein_coding | tolerated(0.06) | benign(0.101) | TCGA-D8-A1JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| EHBP1 | SNV | Missense_Mutation | c.1430N>G | p.Ser477Cys | p.S477C | Q8NDI1 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| EHBP1 | SNV | Missense_Mutation | c.713C>T | p.Ser238Leu | p.S238L | Q8NDI1 | protein_coding | tolerated(0.07) | probably_damaging(0.966) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| EHBP1 | SNV | Missense_Mutation | novel | c.34N>C | p.Gly12Arg | p.G12R | Q8NDI1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-LL-A8F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |